Loading
CDA (Cytidine deaminase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms and Myelodysplastic syndromes / neoplasms.
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.92, genetic association 0.00, clinical 0.84).
In plain words · CDA (Cytidine deaminase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms and Myelodysplastic syndromes / neoplasms.
CDA (Cytidine deaminase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms and Myelodysplastic syndromes / neoplasms.
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. Locus 1p36.12 (HGNC).
No product in this corpus aims at CDA yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CDA: RNA tissue enhanced (bone marrow 183 nTPM, esophagus 108 nTPM, liver 81 nTPM); blood lineage lineage enriched (granulocytes 1,240 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (myelodysplastic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CDA tissue; Open Targets ENSG00000158825 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Kuhn et al, Biochem. Biophys. Res. Commun, 1993, "Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as a marker of monocyte/macrophage differentiation". Source.
Sources: HGNC HGNC:1712 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P32320 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000158825 (association with cancer (MONDO_0004992) 0.54; per-cancer scores at or above 0.5: myelodysplastic syndrome 0.51, myeloproliferative neoplasm 0.53, leukaemia 0.53 (GraphQL API, CC0))
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. Locus 1p36.12 (HGNC).
RNA: tissue enhanced (bone marrow 183 nTPM, esophagus 108 nTPM, liver 81 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 1,240 nTPM).
No normal tissue stained high; medium in Bone marrow.
No cancer sample stained medium or high.
HPA CDA tissue · HPA CDA pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CDA" OR ABSTRACT:"CDA" OR TITLE:"cytidine deaminase" OR ABSTRACT:"cytidine deaminase" OR TITLE:"Cytidine deaminase" OR ABSTRACT:"Cytidine deaminase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDA, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.